Non-Hodgkin Lymphoma

Show Only Open Trials
1.

A Phase 2, Multi-center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant followed by Maintenance Therapy with romidepsin for the Treatment of T-cell Non-Hodgkin Lymphoma (NHL)

  • Study Status: Open to Enrollment
  • Sponsor: Memorial Sloan Kettering Cancer Center
  • Disease Status and/or Stage: Non-Hodgkin's Lymphoma
3.

Gilead 0125: A Study Evaluating the Efficacy and Safety of Idelalisib(GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Previously Treated Indolent non-Hodgkin Lymphoma
  • Protocol ID: Gilead 0125
4.

Gilead 0124: A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Previously Treated Indolent non-Hodgkin Lymphoma
  • Protocol ID: Gilead 0124
6.

A051103: A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Alliance for Clinical Trials in Oncology
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: A051103
7.

Alliance A051202: A Phase I Trial of Lenalidomide, Rituximab, and Idelalisib in Recurrent Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Alliance for Clinical Trials in Oncology
  • Disease Status and/or Stage: Recurrent Follicular non-Hodgkin Lymphoma
  • Protocol ID: A051202
8.

A Phase Ib/IIa Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Memorial Sloan-Kettering Cancer Center
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoma and Multiple Myeloma
9.

An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects with Relapsed or Refractory Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Janssen and Pharmacyclics
  • Disease Status and/or Stage: Relapsed or Refractory Mantle Cell Lymphoma
  • Protocol ID: PCI-32765MCL4001
10.

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: OncoMed
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoid Malignancies, Including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Transformed Mycosis Fungoides (MF), or Sezary Syndrome
  • Protocol ID: 52M51-001
11.

An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Janssen
  • Disease Status and/or Stage: Refractory Follicular Lymphoma
  • Protocol ID: PCI-32765FLR2002
13.

A Multicenter Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated with Rituximab and Vincristine

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma or Burkitt Lymphoma
  • Protocol ID: C14011
14.

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell Lymphoma
  • Protocol ID: C14012
15.

A Randomized study of Combined Haplo-identical Umbilical Cord Transplantation vs. Double Umbilical Cord Transplantation in Patients with Hematologic Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
16.

BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals

  • Study Status: Open to Enrollment
  • Sponsor: BMT-CTN
  • Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
  • Protocol ID: BMT CTN 0903
17.

CALGB 50901: A Phase II Trial of Ofatumumab (CALGB IND #112390) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: CALGB 50901
18.

S1108: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: SWOG
  • Disease Status and/or Stage: Relapsed/Refractory Peripheral T-Cell non-Hodgkin Lymphoma
20.

CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: CALGB 50904
21.

A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo diffuse Large B-Cell Lymphoma (PCYC 1106)

  • Study Status: Closed to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Relapsed or Refractory de Novo Diffuse Large B-cell Lymphoma (DLBCL)
22.

Phase II Study of Lenalidomide plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated Mantle Cell Lymphoma
23.

An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

  • Study Status: Closed to Enrollment
  • Sponsor: Millennium Pharmaceuticals
  • Disease Status and/or Stage: Previously untreated Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
24.

Phase 1 Study of PD 0332991 Plus Bortezomib in Patients with Previously Treated Mantle Cell Lymphoma

  • Study Status: Closed to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)

Top of page